论文部分内容阅读
本文报道术前用争光霉素—Ⅲ治疗28例食管癌,其中23例行手术切除。23例手术标本镜下观察,见癌实质重度退变者7侧(其中1例癌细胞见不同程度的空泡样变)、中度退变7例、轻度退变6例和无变化3例。癌周间质反应强烈者5例、中度8例、微弱8例和无反应2例。23例食管旁淋巴结中,5例有转移癌,其中3例重度退变、1例轻度退变;此3例淋巴结皆见明显纤维组织增生和胶元化。无转移的淋巴结中,3例有SH反应,12例淋巴滤泡增生扩大。作者认为争光霉素—Ⅲ对鳞癌的疗效机制可能有促使癌细胞从异常角化转向正常角化的作用。从而延缓癌的生长速度。从间质反应看,此药对肿瘤宿主的细胞免疫并无明显抑制现象。
This article reports premedication with bleomycin-III treatment of 28 cases of esophageal cancer, of which 23 cases were surgically removed. Microscopically observed in 23 cases of surgical specimens, we found 7 cases of severe degenerative carcinomas (including 1 case of cancerous cells with varying degrees of vacuolar degeneration), 7 cases of moderate degeneration, 6 cases of mild degeneration and 3 cases of no change example. Periplasmic cancer reaction in 5 cases, moderate in 8 cases, weak in 8 cases and no reaction in 2 cases. In 23 cases of esophageal lymph nodes, 5 cases had metastatic carcinoma, of which 3 cases had severe degeneration and 1 case mild degeneration. The three cases had obvious fibrous tissue hyperplasia and gelatinization. Among the non-metastatic lymph nodes, 3 had SH response and 12 had lymphoid follicular hyperplasia. The authors believe that the mechanism of effect of bleomycin-III on squamous cell carcinoma may be to promote cancer cells from the abnormal keratosis to the role of normal keratosis. Thus slowing the growth of cancer. From the interstitial reaction, this drug has no significant inhibition on the cellular immunity of the tumor host.